From: Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)
 | Placebo, n (%) | hLF1-11, 0.005 mg, n (%) | hLF1-11, 0.05 mg, n (%) | hLF1-11, 0.5 mg, n (%) | hLF1-11, 5 mg, n (%) |
---|---|---|---|---|---|
Study 1 (single dosing): | Â | Â | Â | Â | Â |
Subjects per group | 8 (100) | 6 (100) | 6 (100) | 6 (100) | 6 (100) |
Diarrhoea | - | 1 (16.7) | - | - | - |
Dizziness | - | - | - | - | 1 (16.7) |
Epistaxis | 1 (12.5) | - | - | - | - |
Feeling cold | - | 1 (16.7) | - | - | - |
Flatulence | - | - | - | - | 1 (16.7) |
Headache | 1 (12.5) | 1 (16.7) | - | - | 1 (16.7) |
Increased appetite | 1 (12.5) | - | - | - | - |
Phlebitis | - | - | - | - | 1 (16.7) |
Purpura | - | - | - | - | 1 (16.7) |
Somnolence | 1 (12.5) | - | - | - | 1 (16.7) |
Study 2 (multiple dosing): | Â | Â | Â | Â | Â |
Subjects per group | 3a (100) | Â | Â | 6 (100) | 7a (100) |
ALT increase | - | Â | Â | 2 (33.3) | 3 (42.9) |
AST increase | - | Â | Â | - | 1 (14.3) |
Dry skin | 1 (33.3) | Â | Â | 1 (16.7) | - |
Hyperhydrosis | - | Â | Â | 1 (16.7) | - |
Injection site erythaema | 1 (33.3) | Â | Â | - | - |
Injection site pain | 1 (33.3) | Â | Â | - | - |
Injection site reaction | - | Â | Â | 2 (33.3) | 1 (14.3) |
Malaise | - | Â | Â | 1 (16.7) | - |
Nausea | - | Â | Â | 1 (16.7) | - |